Human fibroblast growth factor market seen topping $1.83B by 2030

By AI, Created 11:31 AM UTC, May 27, 2026, /AGP/ – The Business Research Company says the human fibroblast growth factor market will rise from $1.1 billion in 2025 to $1.22 billion in 2026, then reach $1.83 billion by 2030. The forecast points to growing demand in regenerative medicine, tissue engineering, and drug screening, with North America leading now and Asia-Pacific expected to grow fastest.

Why it matters: - The human fibroblast growth factor market is expanding as biotech, regenerative medicine, and research applications widen. - Growth in the market tracks with rising chronic disease rates, which increase demand for tissue repair and inflammation-related therapies. - The forecast suggests more use of recombinant hFGF products in medical and research workflows through 2030.

What happened: - The Business Research Company released a 2026 report on the human fibroblast growth factor market. - The market is projected to grow from $1.1 billion in 2025 to $1.22 billion in 2026. - The report forecasts the market will reach $1.83 billion by 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - The report links recent growth to regenerative medicine research, demand for proteins derived from human tissue, biotech R&D spending, expansion of hospital and research networks, and broader use of hFGF in diagnostics. - The forecast period is supported by rising adoption of recombinant hFGF, growth in tissue engineering and cell therapy, stronger demand for high-throughput drug screening, better protein stabilization technologies, and wider direct sales and e-commerce channels. - The report highlights new recombinant hFGF variants, broader tissue engineering use, high-purity and lyophilized formulations, drug screening platforms, and cell proliferation research as areas to watch. - Human fibroblast growth factor is described as a group of naturally occurring proteins that support cell growth and development. - hFGF binds to fibroblast growth factor receptors on the cell surface and triggers signals that regulate cell proliferation, survival, and angiogenesis. - The chronic disease driver matters because hFGF can support tissue repair, blood vessel formation, and inflammation reduction. - The Northern Arizona Medical Group said nearly 75% of the global population is expected to live with at least one chronic disease by 2025. - U.S. data from 2023 showed 76.4% of adults had at least one chronic condition and 51.4% had two or more. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The report package includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables. - The company also listed related 2026 reports on adeno-associated virus vectors in gene therapy, gastric cancer therapy, and over-the-counter drugs. - A free sample and the full report are available via the sample request page and the full report.

Between the lines: - The market outlook reflects a shift from basic research use toward more commercialized applications in screening, cell therapy, and distribution. - North America’s current lead suggests a mature base of biotech demand, while Asia-Pacific’s projected pace points to expanding research and healthcare capacity. - The heavy emphasis on recombinant products and high-purity formulations indicates the market is moving toward more standardized, scalable supply.

What’s next: - The report expects more product development around recombinant variants, stabilized proteins, and lyophilized formats. - Broader use in tissue engineering and cell proliferation research should continue to shape demand through 2030. - Distribution is likely to keep shifting toward direct sales and e-commerce as buyers seek easier access to research-grade materials.

The bottom line: - Human fibroblast growth factor is moving from a specialized research input toward a broader biotech and therapeutic market, with the report projecting sustained double-digit growth through 2030.